Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (Nasdaq: PYXS) is a clinical-stage biopharmaceutical company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, with a lead focus on recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). This news page aggregates company-issued updates, press releases, and other coverage related to Pyxis Oncology’s oncology pipeline and corporate activities.
Readers can find announcements on preliminary and updated clinical data for micvotabart pelidotin (MICVO), the company’s first-in-concept ADC targeting extradomain-B of fibronectin in the tumor extracellular matrix. News items include results from Phase 1 monotherapy and Phase 1/2 combination studies in R/M HNSCC and other advanced solid tumors, as well as translational findings on MICVO’s three-pronged mechanism of action involving direct tumor cell killing, bystander effects, and immunogenic cell death.
In addition to clinical trial readouts, this feed features business and financial updates such as quarterly results, cash runway commentary, milestone payments from collaboration and license agreements, and information on royalty-related transactions. Corporate developments, including inducement equity grants, governance matters, and participation in investor and industry conferences, are also reflected in Pyxis Oncology’s news flow.
For investors, analysts, and others following PYXS, the news stream offers a consolidated view of how the company is advancing MICVO in monotherapy and in combination with pembrolizumab under a Clinical Trial Collaboration Agreement with Merck, as well as how it positions itself within the broader field of ADC-based cancer therapeutics. Regularly reviewing this page can help users track key clinical milestones, scientific presentations, and corporate disclosures that shape the company’s oncology development story.
Pyxis Oncology, Inc. (Nasdaq: PYXS) will be presenting at the RBC Capital Markets Global Healthcare Conference where the President and CEO will participate in a fireside chat and host investor meetings. The event will take place on May 14, 2024, at 3:05 PM ET.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.